Focusing on the fundamentals: what do and don’t we know about mRNA delivery?

Update: 2024-03-11

Description

As excitement around the evolving field of mRNA continues to grow, there remain some
fundamental questions to be answered. David McCall, Senior Editor, Nucleic Acid Insights, spoke with Monash University’s Colin Pouton, Professor of Pharmaceutical Biology and Angus Johnston, Associate Professor, ARC Future Fellow about the key limitations and unknowns of current mRNA delivery approaches, and critical areas for further research and innovation to propel the field forward.

Comments

In Channel

Exploring advances in bioconjugation: nanozymes, tissue tropism, and the future of responsive systems

2025-10-0115:29

The promise of antibody-oligonucleotide conjugates for neurological diseases

2025-08-2721:22

From innovation to access: bridging gaps in scalability and cold chain precision logistics for advanced therapies

2025-07-1819:49

Enhancing mRNA results through strategic RNA design and quality control

2025-03-2712:53

For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications

2025-03-1319:09

Exploring challenges, opportunities and state-of-the-art tools in the lipid nanoparticle space

2025-02-1915:03

Driving innovation in cell and gene therapy: the role of AI and robotics

2025-01-2715:38

Spatial mapping: shaping the future of I-O diagnostics and treatment

2024-12-0638:44

Pioneering quality control in biomanufacturing of cell and gene therapies

2024-12-0528:08

Preparing for tomorrow’s cell and gene therapies today: lessons from 30 years in the field

2024-09-0625:36

Insights into advanced therapies in the context of evolving funding and M&A environments

2024-06-1422:37

Fit for function: developing potency assays reflective of the in vivo environment

2024-05-1028:20

Gene therapy is having a monumental year: how can the industry keep up with supply?

2024-04-0423:36